DGIdb - ABATACEPT Drug Record

ABATACEPT chembl:CHEMBL1201823 ApprovedImmunotherapy

Alternate Names:

RG-2077
ORENCIA
ABATACEPT (GENETICAL RECOMBINATION)
CTLA4-IGG4M
BMS-188667
ABATACEPT
ORENCIA CLICKJECT
RG-1046
CTLA4IGG4M
CTLA4-IG
CTLA4IG
drugbank:01281
chemidplus:332348-12-6
chembl:CHEMBL1201823
rxcui:614391

Drug Info:

FDA Approval	not approved
Drug Class	protein
Drug Indications	immunosuppressant
Year of Approval	2005
Drug Class	antirheumatic agents
FDA Approval	approved
Drug Class	fusion protein
Drug Indications	antiinflammatory agent,DMARD

(3 More Sources)

Publications:

Lumsden et al., 2000, Differential requirement for CD80 and CD80/CD86-dependent costimulation in the lung immune response to an influenza virus infection., J. Immunol.
Nogid et al., 2006, Role of abatacept in the management of rheumatoid arthritis., Clin Ther
Kremer, 2005, Selective costimulation modulators: a novel approach for the treatment of rheumatoid arthritis., J Clin Rheumatol
Scheinfeld, 2006, Abatacept: A review of a new biologic agent for refractory rheumatoid arthritis for dermatologists., J Dermatolog Treat
Vincenti et al., 2007, T cell costimulation: a rational target in the therapeutic armamentarium for autoimmune diseases and transplantation., Annu. Rev. Med.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Reynolds et al., 2007, Abatacept: a novel treatment for moderate-to-severe rheumatoid arthritis., Pharmacotherapy
Weyand et al., 2006, T-cell-targeted therapies in rheumatoid arthritis., Nat Clin Pract Rheumatol
Hervey et al., 2006, Abatacept., BioDrugs
Maxwell et al., 2010, Abatacept for rheumatoid arthritis: a Cochrane systematic review., J. Rheumatol.
Kasai et al., 1998, Blockade of CD28/B7 interaction suppresses allergic eosinophilic inflammation in mice., Int. Arch. Allergy Immunol.

ABATACEPT CD80

Interaction Score: 38.64

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Trial Name CTLA4

Novel drug target Established target

Direct Interaction yes

PMIDs:
10604996 17212998 16357751 16971318 17020493 11752352 18041889 16932686 16573350 20080922

Sources:
TdgClinicalTrial ChemblInteractions NCI TEND TTD
ABATACEPT CD86

Interaction Score: 38.28

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction T-lymphocyte activation antigen CD86 inhibitor

Trial Name Orencia

PMIDs:
17212998 16357751 16971318 17020493 11752352 18041889 16932686 16573350 20080922

Sources:
TdgClinicalTrial ChemblInteractions TEND TTD
ABATACEPT CTLA4

Interaction Score: 2.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9758890

Sources:
NCI

TEND: ABATACEPT
- Version: 01-August-2011
Alternate Names:

ABATACEPT Primary Drug Name

Drug Info:

Drug Class antirheumatic agents

Year of Approval 2005

Publications:
TdgClinicalTrial: RG-2077
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications immunosuppressant

Drug Class protein

FDA Approval not approved

Publications:
TdgClinicalTrial: ABATACEPT
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antiinflammatory agent,DMARD

Drug Class fusion protein

FDA Approval approved

Publications:

NCI: CTLA4-IG

Version: 14-September-2017

Alternate Names:

C28898 NCI drug code

Drug Info:

Publications:

Lumsden et al., 2000, Differential requirement for CD80 and CD80/CD86-dependent costimulation in the lung immune response to an influenza virus infection., J. Immunol.

Kasai et al., 1998, Blockade of CD28/B7 interaction suppresses allergic eosinophilic inflammation in mice., Int. Arch. Allergy Immunol.

TTD: Abatacept
- Version: 2020.06.01
Alternate Names:

D0EW4L TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1201823
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL1201823
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Trial Name	CTLA4
Novel drug target	Established target
Direct Interaction	yes

Direct Interaction	yes
Mechanism of Interaction	T-lymphocyte activation antigen CD86 inhibitor
Trial Name	Orencia

antagonist (inhibitory)
inhibitor (inhibitory)

antagonist (inhibitory)
inhibitor (inhibitory)

ABATACEPT Drug Record

ABATACEPT chembl:CHEMBL1201823 ApprovedImmunotherapy

Alternate Names:

Drug Info:

Publications:

ABATACEPT CD80

Interaction Types & Directionality: antagonist (inhibitory) inhibitor (inhibitory)

Interaction Info: Trial Name CTLA4 Novel drug target Established target Direct Interaction yes

PMIDs: 10604996 17212998 16357751 16971318 17020493 11752352 18041889 16932686 16573350 20080922

Sources: TdgClinicalTrial ChemblInteractions NCI TEND TTD

ABATACEPT CD86

Interaction Types & Directionality: antagonist (inhibitory) inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction T-lymphocyte activation antigen CD86 inhibitor Trial Name Orencia

PMIDs: 17212998 16357751 16971318 17020493 11752352 18041889 16932686 16573350 20080922

Sources: TdgClinicalTrial ChemblInteractions TEND TTD

ABATACEPT CTLA4

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9758890

Sources: NCI

TEND: ABATACEPT

Alternate Names: ABATACEPT Primary Drug Name

Drug Info: Drug Class antirheumatic agents Year of Approval 2005

Publications:

TdgClinicalTrial: RG-2077

Alternate Names:

Drug Info: Drug Indications immunosuppressant Drug Class protein FDA Approval not approved

Publications:

TdgClinicalTrial: ABATACEPT

Alternate Names:

Drug Info: Drug Indications antiinflammatory agent,DMARD Drug Class fusion protein FDA Approval approved

Publications:

NCI: CTLA4-IG

Alternate Names: C28898 NCI drug code

Drug Info:

TTD: Abatacept

Alternate Names: D0EW4L TTD Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL1201823

Alternate Names:

Drug Info:

Publications:

ChemblInteractions: CHEMBL1201823

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Trial Name CTLA4

Novel drug target Established target

Direct Interaction yes

PMIDs:
10604996 17212998 16357751 16971318 17020493 11752352 18041889 16932686 16573350 20080922

Sources:
TdgClinicalTrial ChemblInteractions NCI TEND TTD

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction T-lymphocyte activation antigen CD86 inhibitor

Trial Name Orencia

PMIDs:
17212998 16357751 16971318 17020493 11752352 18041889 16932686 16573350 20080922

Sources:
TdgClinicalTrial ChemblInteractions TEND TTD

Interaction Types & Directionality:

n/a

PMIDs:
9758890

Sources:
NCI

Alternate Names:

ABATACEPT Primary Drug Name

Drug Info:

Drug Class antirheumatic agents

Year of Approval 2005

Drug Info:

Drug Indications immunosuppressant

Drug Class protein

FDA Approval not approved

Drug Info:

Drug Indications antiinflammatory agent,DMARD

Drug Class fusion protein

FDA Approval approved

Alternate Names:

C28898 NCI drug code

Alternate Names:

D0EW4L TTD Drug ID